Trading in Novo Nordisk shares by board members, executives and associated persons on 15 February 2021
Bagsværd, Denmark, 17 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their
associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.
Please find below a statement of such trading in shares issued by Novo Nordisk.
|1||Details of the person discharging managerial responsibilities/person closely associated|
|a)||Name of the Board member/Executive/Associated Person||Maha Kutay|
|2||Reason for the notification|
|a)||Position/status||Closely related to Kasim Kutay, member of the Board of Directors|
|b)||Initial notification/Amendment||Amendment to company announcement no. 12 / 2021 which erroneously stated Kasim Kutay in section 1a)|
|3||Details of the issuer|
|a)||Name||Novo Nordisk A/S|
|4||Details of the transaction(s)|
Description of the financial instrument,
type of instrument,
|Identification code||Novo Nordisk B DK0060534915|
|b)||Nature of the transaction||Purchase of shares|
|c)||Price(s) and volume(s)|
|DKK 463.11||552 shares|